The estimated Net Worth of Robert D. Ciappenelli is at least $4.18 millió dollars as of 15 December 2021. Mr. Ciappenelli owns over 3,425 units of Dicerna Pharmaceuticals Inc stock worth over $613,584 and over the last 5 years he sold DRNA stock worth over $0. In addition, he makes $3,561,510 as Chief Commercial Officer at Dicerna Pharmaceuticals Inc.
Robert has made over 4 trades of the Dicerna Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 3,425 units of DRNA stock worth $130,904 on 15 December 2021.
The largest trade he's ever made was exercising 30,000 units of Dicerna Pharmaceuticals Inc stock on 11 June 2021 worth over $468,300. On average, Robert trades about 6,865 units every 49 days since 2019. As of 15 December 2021 he still owns at least 16,054 units of Dicerna Pharmaceuticals Inc stock.
You can see the complete history of Mr. Ciappenelli stock trades at the bottom of the page.
Robert D. Ciappenelli serves as Chief Commercial Officer of the Company. Prior to that, Mr. Ciappenelli served as Global Head of Commercial at Momenta Pharmaceuticals (“Momenta”) from January 2016 to October 2018. Prior to Momenta, he held several leadership positions at Shire Pharmaceuticals (now part of Takeda), across commercial operations and business planning. Mr. Ciappenelli’s pharmaceutical commercialization experience also includes various leadership positions at Sunovion Pharmaceuticals, where he served as Vice President of Commercial Operations, Executive Director of Commercial Services and Sales Training and Executive Director of Central Nervous System Marketing. Mr. Ciappenelli earned a Bachelor of Business Administration (B.B.A.) in Finance from the University of Massachusetts at Amherst and a Master of Business Administration (M.B.A.) from the Harvard Graduate School of Business Administration.
As the Chief Commercial Officer of Dicerna Pharmaceuticals Inc, the total compensation of Robert Ciappenelli at Dicerna Pharmaceuticals Inc is $3,561,510. There are 1 executives at Dicerna Pharmaceuticals Inc getting paid more, with Douglas Fambrough having the highest compensation of $5,048,130.
Robert Ciappenelli is 53, he's been the Chief Commercial Officer of Dicerna Pharmaceuticals Inc since 2019. There are 9 older and 4 younger executives at Dicerna Pharmaceuticals Inc. The oldest executive at Dicerna Pharmaceuticals Inc is Patrick Gray, 71, who is the Independent Director.
Robert's mailing address filed with the SEC is C/O DICERNA PHARMACEUTICALS, INC., 75 HAYDEN AVENUE, LEXINGTON, MA, 02421.
Over the last 11 years, insiders at Dicerna Pharmaceuticals Inc have traded over $233,644,011 worth of Dicerna Pharmaceuticals Inc stock and bought 2,456,100 units worth $36,501,331 . The most active insiders traders include Capital Management, Llc Kol..., Nicole Vitullo és Peter Kolchinsky. On average, Dicerna Pharmaceuticals Inc executives and independent directors trade stock every 21 days with the average trade being worth of $4,025,674. The most recent stock trade was executed by Douglas W. Pagan on 15 December 2021, trading 2,050 units of DRNA stock currently worth $78,351.
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. Using its proprietary GalXC™ and GalXC-Plus™ RNAi technologies, Dicerna is committed to developing RNAi-based therapies with the potential to treat both rare and more prevalent diseases. By silencing disease-causing genes, Dicerna's GalXC platform has the potential to address conditions that are difficult to treat with other modalities. Initially focused on disease-causing genes in the liver, Dicerna has continued to innovate and is exploring new applications of its RNAi technology with GalXC-Plus, which expands on the functionality and application of its flagship liver-based GalXC technology, and has the potential to treat diseases across multiple therapeutic areas. In addition to its own pipeline of core discovery and clinical candidates, Dicerna has established collaborative relationships with some of the world's leading pharmaceutical companies, including Novo Nordisk A/S, Roche, Eli Lilly and Company, Alexion Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH and Alnylam Pharmaceuticals, Inc. Between Dicerna and its collaborative partners, they currently have more than 20 active discovery, preclinical or clinical programs focused on rare, cardiometabolic, viral, chronic liver and complement-mediated diseases, as well as neurodegenerative diseases and pain. Dicerna's mission is to interfere - to silence genes, to fight disease, to restore health.
Dicerna Pharmaceuticals Inc executives and other stock owners filed with the SEC include: